196 related articles for article (PubMed ID: 32525557)
1. Secondary plasma cell leukaemia treated with single agent venetoclax.
Glavey SV; Flanagan L; Bleach R; Kelly C; Quinn J; Ní Chonghaile T; Murphy P
Br J Haematol; 2020 Aug; 190(4):e242-e245. PubMed ID: 32525557
[No Abstract] [Full Text] [Related]
2. Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14).
Jelinek T; Mihalyova J; Kascak M; Duras J; Popkova T; Benkova K; Richterova P; Plonkova H; Zuchnicka J; Broskevicova L; Huvarova L; Cerna L; Growkova K; Simicek M; Havel M; Gumulec J; Navratil M; Koristek Z; Paiva B; Hajek R
Am J Hematol; 2019 Jan; 94(1):E35-E37. PubMed ID: 30370955
[No Abstract] [Full Text] [Related]
3. Natural history of multiple myeloma patients refractory to venetoclax: A single center experience.
Maples KT; Nooka AK; Gupta V; Joseph NS; Heffner LT; Hofmeister C; Dhodapkar M; Matulis SM; Lonial S; Boise LH; Kaufman JL
Am J Hematol; 2021 Mar; 96(3):E68-E71. PubMed ID: 33275813
[No Abstract] [Full Text] [Related]
4. Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma.
Kaufman JL; Gasparetto C; Schjesvold FH; Moreau P; Touzeau C; Facon T; Boise LH; Jiang Y; Yang X; Dunbar F; Vishwamitra D; Unger S; Macartney T; Pesko J; Yu Y; Salem AH; Ross JA; Hong WJ; Maciag PC; Pauff JM; Kumar S
Am J Hematol; 2021 Apr; 96(4):418-427. PubMed ID: 33368455
[TBL] [Abstract][Full Text] [Related]
5. Multiple myeloma with t(11;14)-associated immature phenotype has lower CD38 expression and higher BCL2 dependence.
Kitadate A; Terao T; Narita K; Ikeda S; Takahashi Y; Tsushima T; Miura D; Takeuchi M; Takahashi N; Matsue K
Cancer Sci; 2021 Sep; 112(9):3645-3654. PubMed ID: 34288263
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy incorporating Bcl-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14).
Gonsalves WI; Buadi FK; Kumar SK
Eur J Haematol; 2018 Feb; 100(2):215-217. PubMed ID: 29064593
[TBL] [Abstract][Full Text] [Related]
7. Venetoclax, bortezomib and S63845, an MCL1 inhibitor, in multiple myeloma.
Wong KY; Chim CS
J Pharm Pharmacol; 2020 May; 72(5):728-737. PubMed ID: 32066201
[TBL] [Abstract][Full Text] [Related]
8. Plasma cell leukaemia with t(11;14) not responsive to venetoclax.
Abu Zaanona MI; Patel P
BMJ Case Rep; 2021 Jan; 14(1):. PubMed ID: 33495184
[TBL] [Abstract][Full Text] [Related]
9. Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14).
Touzeau C; Le Gouill S; Mahé B; Boudreault JS; Gastinne T; Blin N; Caillon H; Dousset C; Amiot M; Moreau P
Haematologica; 2017 Mar; 102(3):e112-e114. PubMed ID: 28057737
[No Abstract] [Full Text] [Related]
10. Targeting Bcl-2 for the treatment of multiple myeloma.
Touzeau C; Maciag P; Amiot M; Moreau P
Leukemia; 2018 Sep; 32(9):1899-1907. PubMed ID: 30076373
[TBL] [Abstract][Full Text] [Related]
11. Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14).
Bahlis NJ; Baz R; Harrison SJ; Quach H; Ho SJ; Vangsted AJ; Plesner T; Moreau P; Gibbs SD; Coppola S; Yang X; Al Masud A; Ross JA; Bueno O; Kaufman JL
J Clin Oncol; 2021 Nov; 39(32):3602-3612. PubMed ID: 34388020
[TBL] [Abstract][Full Text] [Related]
12. Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma.
Bajpai R; Sharma A; Achreja A; Edgar CL; Wei C; Siddiqa AA; Gupta VA; Matulis SM; McBrayer SK; Mittal A; Rupji M; Barwick BG; Lonial S; Nooka AK; Boise LH; Nagrath D; Shanmugam M
Nat Commun; 2020 Mar; 11(1):1228. PubMed ID: 32144272
[TBL] [Abstract][Full Text] [Related]
13. Use of venetoclax in t(11;14) positive relapsed/refractory multiple myeloma: A systematic review.
Khan WJ; Ali M; Hashim S; Nawaz H; Hashim SN; Safi D; Inayat A
J Oncol Pharm Pract; 2024 Apr; 30(3):552-561. PubMed ID: 38113108
[TBL] [Abstract][Full Text] [Related]
14. Impact of t(11;14) as a sole and concomitant abnormality on outcomes in multiple myeloma.
Bal S; Giri S; Godby KN; Costa LJ
Br J Haematol; 2021 Oct; 195(1):e113-e116. PubMed ID: 34165783
[No Abstract] [Full Text] [Related]
15. Is venetoclax the new backbone of acute myeloid leukaemia therapy?
Jain P; Mims AS
Lancet Haematol; 2021 Aug; 8(8):e536-e537. PubMed ID: 34329570
[No Abstract] [Full Text] [Related]
16. Venetoclax in upfront induction therapy for primary plasma cell leukemia with t(11;14) or BCL2 expression.
Roy T; An JB; Doucette K; Chappell AM; Vesole DH
Leuk Lymphoma; 2022 Mar; 63(3):759-761. PubMed ID: 35076333
[No Abstract] [Full Text] [Related]
17. Venetoclax for the treatment of multiple myeloma.
Vaxman I; Sidiqi MH; Gertz M
Expert Rev Hematol; 2018 Dec; 11(12):915-920. PubMed ID: 30428277
[No Abstract] [Full Text] [Related]
18. Venetoclax plus bortezomib and dexamethasone in heavily pretreated end-stage myeloma patients without t(11;14): A real-world cohort.
Jelinek T; Popkova T; Duras J; Mihalyova J; Kascak M; Benkova K; Plonkova H; Cerna L; Koristek Z; Simicek M; Hajek R
Hematol Oncol; 2020 Aug; 38(3):412-414. PubMed ID: 32323881
[No Abstract] [Full Text] [Related]
19. BCL2 blockade overcomes MCL1 resistance in multiple myeloma.
Siu KT; Huang C; Panaroni C; Mukaihara K; Fulzele K; Soucy R; Thorburn C; Cidado J; Drew L; Chattopadhyay S; Raje N
Leukemia; 2019 Aug; 33(8):2098-2102. PubMed ID: 30816329
[No Abstract] [Full Text] [Related]
20. First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia.
Boidol B; Kornauth C; van der Kouwe E; Prutsch N; Kazianka L; Gültekin S; Hoermann G; Mayerhoefer ME; Hopfinger G; Hauswirth A; Panny M; Aretin MB; Hilgarth B; Sperr WR; Valent P; Simonitsch-Klupp I; Moriggl R; Merkel O; Kenner L; Jäger U; Kubicek S; Staber PB
Blood; 2017 Dec; 130(23):2499-2503. PubMed ID: 28972014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]